Hematopoietic Cell Transplantation for Ovarian Cancer — CPB 0635 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0635 governing hematopoietic cell transplantation for ovarian cancer, effective December 12, 2025. Autologous transplants (CPT 38232, 38241) remain covered for specific germ cell tumor indications — but allogeneic transplants and all epithelial ovarian cancer indications are flat denials. Here's what your billing team needs to know.

---

Aetna's updated hematopoietic cell transplantation coverage policy under CPB 0635 Aetna draws a hard line: covered autologous transplantation for germ cell tumors of the ovary under three specific scenarios, and experimental for everything else. The real exposure here is the epithelial ovarian cancer category — it's the most common ovarian cancer type, and Aetna considers transplantation for it unproven across the board, autologous or allogeneic. If your oncology or transplant program bills CPT 38241 or 38232 for those patients, expect claim denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Hematopoietic Cell Transplantation for Ovarian Cancer
Policy Code	CPB 0635 Aetna
Change Type	Modified
Effective Date	December 12, 2025
Impact Level	High — transplant programs and oncology billing teams with Aetna commercial volume
Specialties Affected	Gynecologic oncology, bone marrow/stem cell transplant, hematology, radiation oncology
Key Action	Audit active Aetna prior authorization requests and charge capture for CPT 38232 and 38241 against covered indications before billing

---

Aetna Hematopoietic Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025

The Aetna hematopoietic cell transplantation coverage policy under CPB 0635 covers autologous HCT — but only for germ cell tumors of the ovary, and only in three specific clinical situations. Medical necessity is not a blanket determination here. The indication, tumor type, and disease status at time of transplant all drive the coverage decision.

Aetna considers autologous HCT medically necessary when:

#	Covered Indication Copy
1	The patient has relapsed germ cell tumors of the ovary that responded to standard chemotherapy — this is the salvage setting
2	The patient has germ cell tumors of the ovary in complete remission and is receiving autologous HCT as consolidation therapy
3	The patient has relapsed germ cell tumors of the ovary and is receiving tandem autologous HCT

CPT 38241 (autologous hematopoietic progenitor cell transplantation) and CPT 38232 (bone marrow harvesting for transplantation, autologous) are the covered codes when these criteria are met. Documentation of disease status — specifically whether the patient is in complete remission or relapse, and whether prior chemotherapy produced a response — is not optional. That documentation is what gets your claim paid.

Prior authorization is standard for transplant procedures under Aetna commercial plans. Don't submit CPT 38241 or 38232 without confirmed prior auth tied to the correct indication. A prior authorization approved for "ovarian cancer" without the germ cell tumor specification is not enough — Aetna's reviewers will look at histology.

Reimbursement for these procedures is significant, which makes the stakes high when an authorization is approved under the wrong indication category. Get the tumor type documented in the auth request and in the clinical record before the transplant date.

---

Aetna Hematopoietic Cell Transplantation Exclusions and Non-Covered Indications

This is where the policy gets financially dangerous for billing teams. Three categories are explicitly experimental, investigational, or unproven under CPB 0635. Aetna will deny claims in all three.

First: Autologous HCT as initial treatment for germ cell tumors of the ovary. This means front-line transplantation — using HCT instead of a standard first-line chemotherapy regimen with FDA-approved drugs. Aetna is not paying for that. If a physician plans to skip standard-dose chemotherapy and go straight to transplant, that's an experimental indication under this policy.

Second: Allogeneic HCT for germ cell tumors of the ovary. CPT 38240 (allogeneic HPC transplantation) and CPT 38205 (allogeneic blood-derived HPC harvesting) are not covered for this indication. Period. No combination of documentation or peer-to-peer review changes that under the current policy language.

Third: HCT for epithelial ovarian cancers — the most important exclusion for volume billing teams. Epithelial ovarian cancer accounts for roughly 90% of ovarian cancer cases. Aetna considers both autologous and allogeneic HCT experimental for this tumor type. If your transplant program is treating epithelial ovarian cancer patients with HCT and billing Aetna, those claims will not pay.

The real issue here is documentation at intake. Your prior auth team needs to confirm tumor histology — germ cell vs. epithelial — before initiating the authorization process. Submitting an auth request for an epithelial ovarian cancer patient wastes everyone's time and sets up a denial.

---

Coverage Indications at a Glance

---

Aetna Hematopoietic Cell Transplantation Billing Guidelines and Action Items 2025

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Hematopoietic Cell Transplantation Under CPB 0635

Covered CPT Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
38232	CPT	Bone marrow harvesting for transplantation; autologous
38241	CPT	Hematopoietic progenitor cell (HPC); autologous transplantation

Not Covered / Experimental CPT Codes

Code	Type	Description	Reason Copy
38205	CPT	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic	Not covered for ovarian cancer indications per CPB 0635
38240	CPT	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor	Not covered for ovarian cancer indications per CPB 0635

Other CPT Codes Related to CPB 0635

These codes appear in the policy and may be used in conjunction with covered transplant procedures. Coverage depends on the primary transplant indication being met.

The chemotherapy administration codes (96401 through 96464) are listed as related codes in the policy — they appear because conditioning regimens prior to transplant are part of the overall treatment episode. Their coverage is not governed by CPB 0635 directly. Bill them per your standard Aetna chemotherapy billing guidelines and applicable authorization requirements.

Note on ICD-10-CM codes: The policy lists 10 ICD-10-CM codes in the source document, but the specific codes and descriptions were not included in the available policy data. Pull the full CPB 0635 document from Aetna's provider portal to confirm which ovarian cancer diagnosis codes Aetna associates with covered vs. non-covered indications. Confirm your ICD-10-CM coding maps to germ cell tumor histology — not general ovarian malignancy — for covered claims.

---